The estimated Net Worth of Robert Aspbury is at least $6.99 Milión dollars as of 1 April 2024. Robert Aspbury owns over 16,498 units of Certara stock worth over $3,226,660 and over the last 4 years Robert sold CERT stock worth over $3,764,486.
Robert has made over 8 trades of the Certara stock since 2021, according to the Form 4 filled with the SEC. Most recently Robert exercised 16,498 units of CERT stock worth $181,148 on 1 April 2024.
The largest trade Robert's ever made was selling 21,554 units of Certara stock on 11 November 2021 worth over $852,676. On average, Robert trades about 9,565 units every 68 days since 2021. As of 1 April 2024 Robert still owns at least 293,867 units of Certara stock.
You can see the complete history of Robert Aspbury stock trades at the bottom of the page.
Robert's mailing address filed with the SEC is C/O CERRTARA, INC., 4 RADNOR CORPORATE CENTER, SUITE 350, RADNOR, PA, 19087.
Over the last 5 years, insiders at Certara have traded over $2,048,278,243 worth of Certara stock and bought 97,245 units worth $1,908,085 . The most active insiders traders include Avatar Parent L.P.Eqt Avata..., James E Iii Cashman a Mason P Slaine. On average, Certara executives and independent directors trade stock every 14 days with the average trade being worth of $7,828,136. The most recent stock trade was executed by Leif E Pedersen on 9 September 2024, trading 51,224 units of CERT stock currently worth $578,319.
Certara Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, and Australia. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Certara executives and other stock owners filed with the SEC include: